VALENCIA, Calif., Jan. 11, 2018 /PRNewswire/ -- Bioness, Inc., the leading provider of state-of-the-art, clinically supported rehabilitation and pain management medical devices, today announced several clinical experts will present data from four unique studies demonstrating the clinical benefits of the company's StimRouter® Neuromodulation System at the 2018 North American Neuromodulation Society's (NANS) Annual Meeting in Las Vegas, Nevada. Between January 11th-14th, clinicians from leading medical institutions will showcase the surgical approach techniques and associated clinical results that reinforce the ability of StimRouter to provide significant relief to patient suffering from peripheral nerve pain.
Studies conducted by researchers from the Icahn School of Medicine at Mt. Sinai, Stanford Medical School, the University of Toronto, and The Pain Management Center examined how the StimRouter can be applied to chronic pain conditions, originating from the peripheral nerve region of the shoulder, tibia and other areas of the body.
Topics involving the effects of the StimRouter to be presented during the NANS poster session are:
"The need to support patients in chronic pain with treatments—proven through careful research—is critical for pain management. Patients have a better understanding of how the treatment process works and are taking an active role in their care by asking for data-supported solutions when traditional, temporary therapies are providing marginal returns on pain relief," said Dr. Youssef Josephson, DO, clinician at The Pain Management Center which has clinics throughout the state of New Jersey. "With a resurgence of Peripheral Nerve Stimulation therapy over the last few years, the StimRouter is a promising solution for patients in chronic pain who are not finding significant relief with other therapies."
"Physicians who treat chronic pain patients are not just looking for FDA approved treatments, but also innovations that are continuously studied to demonstrate further independent validation," said Todd Cushman, President and CEO at Bioness. "We are thrilled to support the findings of these medical professionals and are confident their work will result in more physicians being educated on the benefits of StimRouter and more patients gaining access to this critical technology and the durable pain relief it offers."
StimRouter was the first FDA cleared, long-term, minimally invasive peripheral nerve stimulator indicated to treat chronic pain of a peripheral nerve origin, excluding the cranial facial region. This non-drug, patient-controlled medical device is an adjunct to other modes of therapy and is being well received by patients and clinicians alike.
For more information on the StimRouter or to speak with a patient currently using the device, stop by Bioness' booth #317 at NANS or visit www.stimrouter.com.
About StimRouter® Neuromodulation System
The StimRouter Neuromodulation System is indicated for pain management in adults who have severe intractable chronic pain of peripheral nerve origin, as an adjunct to other modes of therapy (e.g. medications). The StimRouter is not intended to treat pain in the craniofacial region. StimRouter is a minimally invasive neuromodulation medical device consisting of a thin, implanted lead with conductive electrode, external pulse transmitter (EPT), and hand-held wireless patient programmer. Electrical signals are transmitted transdermally from the EPT through the electrode, down the lead to the target nerve. StimRouter is programmed at the direction of the physician to meet patient requirements but is controlled by the patient to address the patients' specific, changing pain management needs.
About Bioness, Inc.
Bioness is the leading provider of innovative technologies helping people regain mobility and independence. Bioness solutions include implantable and external neuromodulation systems, robotic systems and software based therapy programs providing functional and therapeutic benefits for individuals affected by pain, central nervous system disorders and orthopedic injuries. Currently, Bioness offers six medical devices within its commercial portfolio which are distributed and sold on five continents and in over 25 countries worldwide. Our technologies have been implemented in the most prestigious and well-respected institutions around the globe with approximately 90% of the top rehabilitation hospitals in the United States currently using one or more Bioness solution. Bioness has a singular focus on aiding large, underserved customer groups with innovative, evidence-based solutions and we will continue to develop and make commercially available new products that address the growing and changing needs of our customers. Individual results vary. Consult with a qualified physician to determine if this product is right for you. Contraindications, adverse reactions and precautions are available online at www.bioness.com.
Media Relations Contact Information
Next Step Communications
SOURCE Bioness, Inc.